Paclitaxel Enhances Antibody-dependent Cell-mediated Cytotoxicity of Trastuzumab by Rapid Recruitment of Natural Killer Cells in HER2-positive Breast Cancer.

CONCLUSIONS: Adding paclitaxel to trastuzumab significantly enhances ADCC, with levels twice as great as with trastuzumab monotherapy, through a rapid recruitment of NK cells. This finding suggests that the combination of trastuzumab and paclitaxel has a stronger-than-expected synergistic effect in HER2-positive breast cancer. PMID: 25186575 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/25186575?dopt=Abstract

Source: Journal of Nippon Medical School - September 5, 2014 Category: Universities & Medical Training Authors: Miura D, Yoneyama K, Furuhata Y, Shimizu K Tags: J Nippon Med Sch Source Type: research